10/25/2013 6:58:57 AM
Boston Scientific Corp, which is in the midst of an attempted turnaround, reported weak sales of its heart stents and provided a disappointing fourth-quarter company sales forecast, sending its shares almost 7 percent lower on Thursday. The medical device maker also caused market jitters by announcing that Jeffrey Capello, its chief financial officer since early 2010, would resign effective Dec. 31. He will be replaced by Daniel Brennan, the company's corporate controller.
Help employers find you! Check out all the jobs and post your resume.
comments powered by